Non Hodgkin Lymphoma (NHL) Market Growth Trajectory – Insights On Key Drivers, Major Trends, And Top Opportunities
1 Aug, 2023
The global non Hodgkin lymphoma market size is expected to grow from $8.51 billion in 2022 to $9.34 billion in 2023 at a compound annual growth rate (CAGR) of 9.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global non Hodgkin lymphoma market size is expected to reach $12.97 billion in 2027 at a CAGR of 8.6%.
Global Non Hodgkin Lymphoma (NHL) Market Key Driver
The high frequency of non-Hodgkin lymphoma is projected to drive non-Hodgkin lymphoma market growth in the future. It is a type of cancer that develops in the lymphatic system, which is a component of your immune system. The prevalence of non-Hodgkin lymphoma refers to the number of people in a population who have been diagnosed with or are living with the disease at a given moment. Non-Hodgkin lymphoma treatment improves outcomes for people who have already been diagnosed with the disease by targeting and treating cancer cells.
Get a sample of the global non hodgkin lymphoma (NHL) market reportGlobal Non Hodgkin Lymphoma (NHL) Market Segments
The global non hodgkin lymphoma (NHL) market is segmented:
1) By Type: B-Cell Lymphoma, T-Cell Lymphoma
2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
3) By Route of Administration: Oral, Parenteral, Other Routes of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users
6) By Geography: The regions covered in the non hodgkin lymphoma (NHL) market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest share in the global non hodgkin lymphoma (NHL) market.
Major Non Hodgkin Lymphoma (NHL) Industry Players
Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co., Eli Lilly and Co., Novartis AG, GlaxoSmithKline PLC, AbbVie Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc.
Get the full global non hodgkin lymphoma (NHL) market report
Non Hodgkin Lymphoma (NHL) Market Overview
Non-Hodgkin lymphoma is a cancer of the lymphatic system characterized by the abnormal growth of white blood cells. It is a form of cancer that develops in the immune system component of the body's lymphatic system, which is responsible for battling infection.
Non Hodgkin Lymphoma (NHL) Global Market Report 2023 provides data on the global non hodgkin lymphoma (NHL) market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The non hodgkin lymphoma (NHL) market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.